Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03243617
Other study ID # AOB2015-02
Secondary ID
Status Completed
Phase N/A
First received August 1, 2017
Last updated August 8, 2017
Start date December 4, 2015
Est. completion date September 3, 2016

Study information

Verified date August 2017
Source AOBiome LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate the safety, tolerability and efficacy of AO+ Mist administered daily for 4 weeks to improve the appearance of skin afflicted with keratosis pilaris.


Description:

This will be a single center, double-blind, placebo-controlled study in subjects with keratosis pilaris affecting both sides of the body.

Subjects will be screened within 4 weeks of enrollment. Subjects will be seen at the research facility on for the baseline visit and will be asked to return to the site on weeks 1, 2, 3 and 4 for assessments. Test product application will occur for four weeks starting with the day of the baseline visit.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date September 3, 2016
Est. primary completion date June 8, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Male and female subjects =18 and =65 years of age

2. Subject is in good general health

3. Diagnosis of keratosis pilaris involving areas of the body affected bilaterally

4. Subject has Fitzpatrick Skin Type I-VI

5. Willing to refrain from using any treatments, other than the investigational product, including antibiotics, for acne present on the face.

6. Ability to comprehend and comply with procedures

7. Agree to commit to participate in the current protocol

8. Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)

Exclusion Criteria:

1. Male and female subjects under 18 years or over 65 years of age

2. Female subjects who are pregnant or lactating

3. Subjects who have received laser therapy to the KP affected area in the past 1 year

4. Subjects with a concurrent diagnosis of another skin condition or malignancy

5. Subjects with tan or sunburn over the area affected by KPin the past month

6. Subjects with open, non-healing sores or infections at any skin site

7. Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, a-hydroxy/glycolic acid, including lactic acid lotions (Am-Lactin, Lac-Hydrin), urea cream (Carmol 10, Carmol 20, Carmol 40, Urix 40), salicylic acid (Salex lotion), topical corticosteroids within 4 weeks prior to baseline.

8. Treatment with systemic corticosteroids (including intranasal and inhaled corticosteroids) within 4 weeks prior to baseline

9. Treatment with systemic antibiotics or systemic anti-acne drugs or systemic anti-inflammatory drugs within 4 weeks prior to baseline

10. Prescription topical retinoid use on the face or body within 4 weeks of baseline (e.g., tretinoin, tazarotene, adapalene).

11. Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline..

12. Treatment with any investigational drug within 30 days prior to the beginning of the screening period (this includes investigational formulations of marketed products, inhaled and topical drugs)

13. Subjects who are unable to understand the protocol or give informed consent

14. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)

Study Design


Intervention

Other:
Placebo
Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows: LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days. RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days. Subjects may not wash their body with soap and water AFTER the applications
AO+Mist
Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows: LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days. RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days. Subjects may not wash their body with soap and water AFTER the applications

Locations

Country Name City State
United States Skincare Physicians Chestnut Hill Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
AOBiome LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Difference in Skindex16 Quality of Life survey Baseline-Week 4
Primary Number of Participants With Treatment-Related Adverse Events as assessed by physical exam and appearance Baseline-Week 4
Secondary Difference in Keratosis pilaris Investigator Score Baseline-Week 4
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05666011 - Laser to Aid in Treatment of Keratosis Pilaris on Arms N/A
Completed NCT04797663 - Long-pulsed 1064 nm Nd-YAG Laser Versus TCA 20% in Treatment of Keratosis Pilaris Phase 4
Terminated NCT00944216 - Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Phase 4
Active, not recruiting NCT06032078 - Evaluation of the Responsiveness of Investigator Global Assessment Score for Keratosis Pilaris N/A
Recruiting NCT05535517 - Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris